US OptionsDetailed Quotes

CLLS240517P7500 

Watchlist
  • 5.00
  • 0.000.00%
15min DelayTrading Mar 5 14:49 ET
0.00High0.00Low
Intraday
  • 5D
  • 1D

News

Comments

    $Cellectis(CLLS.US)$
    NEWS
    Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
    Cellectis announced the completion of an additional equity investment of $140M by AstraZeneca. AstraZeneca purchased 10,000,000 class A convertible preferred shares and 18,000,000 class B convertible preferred shares at $5.00 per share. This move solidifies AstraZeneca's ownership in Cellectis, giving them approximately 44% of the share capital and 30% of the voting rights in the company.
    $Cellectis(CLLS.US)$
    NEWS
    Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
    Cellectis presents novel TALEN editing processes enabling highly efficient gene correction and gene insertion in HSPCs, showcasing the potential and versatility of the technology for gene therapy. The company will present first data exploring these processes at ASGCT. The editing approaches could revolutionize the treatment of metabolic and neurologica...
    $Cellectis(CLLS.US)$
    NEWS
    Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
    Cellectis (NASDAQ: CLLS) announces a breakthrough in gene-editing therapy with the publication of a new research paper. The study demonstrates the potential of TALEN-mediated intron editing in HSPCs for targeted transgene expression, offering new treatment possibilities for metabolic and neurological diseases.
    $Cellectis(CLLS.US)$ Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
    3 MINUTES AGO, 4:30 PM EDT
    VIA GLOBENEWSWIRE
    NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that...
    Jean Pierre Garnier, Cellectis Chairman, thanked shareholders for supporting the Additional Investment and welcomed Mr. Dunoyer and Dr. Rivers to the board, praising their pharma industry experience.
Read more